- New research in JNCCN sheds light on multi-organ adverse events from immunotherapy – EurekAlert
- New research in JNCCN sheds light on multi-organ adverse events from immunotherapy – EurekAlert
- New research in JNCCN sheds light on multi-organ adverse events from immunotherapy – EurekAlert
- AbbVie signs immunotherapy pact with I-Mab worth $2bn – PMLiVE
